文献速递食管胃疾病与幽门螺杆菌消化道肿瘤与早癌

短效胰高血糖素样肽-1受体激动剂与2型糖尿病患者胃食管反流病及其并发症风险增加相关:一项人群水平回顾性匹配队列研究

Shorter-acting glucagon-like peptide-1 receptor agonists are associated with increased development of gastro-oesophageal reflux disease and its complications in patients with type 2 diabetes mellitus: a population-level retrospective matched cohort study.
PubMed 文献 · Gut · 2024-01-05

利用TriNetX全球数据库纳入1,543,351例成人2型糖尿病患者,倾向性评分匹配后每组177,666例,比较GLP-1受体激动剂与其他二线降糖药。GLP-1 RA暴露与糜烂性反流病风险增加相关(HR 1.15),该风险仅见于短效制剂(HR 1.215),长效制剂无此关联(HR 0.994)。短效GLP-1 RA还与食管狭窄、Barrett食管(伴或不伴异型增生)风险增加相关。

要点

  • 短效GLP-1 RA与糜烂性反流病风险增加相关(HR 1.215;95%CI 1.111-1.328)。
  • 短效GLP-1 RA与食管狭窄、Barrett食管(伴或不伴异型增生)风险增加相关。
  • 长效GLP-1 RA未显示与糜烂性反流病风险增加相关(HR 0.994;95%CI 0.924-1.069)。

核心结论

  • 起始短效GLP-1受体激动剂与胃食管反流病及其并发症风险增加相关。

研究设计与样本

  • 使用TriNetX全球数据库识别成人2型糖尿病患者,生成两个队列共1,543,351例,分别使用GLP-1受体激动剂或其他二线降糖药,采用倾向性评分匹配、Kaplan-Meier分析和Cox比例风险比分析。
  • 倾向性评分匹配后每组177,666例,并分别分析起始短效(半衰期≤1天)和长效(半衰期≥5天)GLP-1受体激动剂的患者结局。

主要发现

  • GLP-1受体激动剂暴露与糜烂性反流病风险增加相关(HR 1.15;95%CI 1.09-1.22)。
  • 糜烂性反流病风险增加仅见于短效GLP-1受体激动剂暴露(HR 1.215;95%CI 1.111-1.328),长效制剂无此关联(HR 0.994;95%CI 0.924-1.069)。
  • 短效GLP-1受体激动剂还与食管狭窄风险增加相关(HR 1.284;95%CI 1.135-1.453)。
  • 短效GLP-1受体激动剂与不伴异型增生的Barrett食管风险增加相关(HR 1.372;95%CI 1.217-1.546),与伴异型增生的Barrett食管风险增加相关(HR 1.505;95%CI 1.164-1.946);长效制剂无这些关联。
  • 该关联在敏感性分析中持续存在,并在单独分析短效GLP-1受体激动剂利拉鲁肽、利司那肽和艾塞那肽时也持续存在。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Shorter half-life glucagon-like peptide-1 receptor agonists (GLP-1 RAs) delay gastric emptying (DGE) more than GLP-1 RAs with longer half-lives. DGE is a known risk factor for gastro-oesophageal reflux disease (GERD) and its complications. AIM: To determine whether short-acting or long-acting GLP-1 RAs are associated with an increased risk of new GERD or GERD-related complications DESIGN: We used the TriNetX global database to identify adult patients with type 2 diabetes mellitus and generated two cohorts totalling 1 543 351 patients on (1) GLP-1 RA or (2) other second-line diabetes medication. Using propensity-score matching, Kaplan-Meier Analysis and Cox-proportional hazards ratio (HR), we analysed outcomes and separately examined outcomes in patients starting short-acting (≤1 day) and long-acting (≥5 days) GLP-1 RAs. RESULTS: 177 666 patients were in each propensity-matched cohort. GLP-1 RA exposure was associated with an increased risk (HR 1.15; 95% CI 1.09 to 1.22) of erosive reflux disease (ERD). However, this was solely due to short-acting (HR 1.215; 95% CI 1.111 to 1.328), but not long-acting (HR 0.994; 95% CI 0.924 to 1.069) GLP-1 RA exposure. Short-acting GLP-1 RAs were also associated with increased risk of oesophageal stricture (HR 1.284; 95% CI 1.135 to 1.453), Barrett's without dysplasia (HR 1.372; 95% CI 1.217 to 1.546) and Barrett's with dysplasia (HR 1.505; 95% CI 1.164 to 1.946) whereas long-acting GLP-1 RAs were not. This association persisted in sensitivity analyses, and when individually examining the short-acting GLP-1 RAs liraglutide, lixisenatide and exenatide. CONCLUSION: Starting shorter-acting GLP-1 RAs is associated with increased risks of GERD and its complications.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Liu BD, Udemba SC, Liang K, et al. Shorter-acting glucagon-like peptide-1 receptor agonists are associated with increased development of gastro-oesophageal reflux disease and its complications in patients with type 2 diabetes mellitus: a population-level retrospective matched cohort study. Gut. 2024. PMID: 37739778. doi:10.1136/gutjnl-2023-329651

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。